Advertisement
ENGN vs INSM
Which Stock Would AI Choose? enGene Therapeutics (ENGN) vs. Insmed (INSM) Stock Comparison
Key Takeaways
- ENGN is a clinical-stage, micro-cap genetic-medicines developer with no approved products, while INSM is a commercial-stage biopharmaceutical company generating hundreds of millions in quarterly revenue.
- Tickeron AI Verdict: Based on trend consistency, commercial traction, and relative market positioning, Tickeron's AI currently favors INSM over ENGN.
- ENGN trades near its 52-week low after a sharp drawdown, while INSM remains well off its highs despite a strong quarterly revenue beat.
- INSM carries a consensus "Strong Buy" analyst rating, whereas ENGN holds a more cautious "Hold" consensus.
- For more context, explore ENGN Major News, ENGN Today's Price Move, INSM Major News, and INSM Today's Price Move.
- To see how automated strategies are positioning across the market, visit the Trending AI Robots page.
Introduction
Investors comparing ENGN and INSM are weighing two very different stages of the biotechnology life cycle. One is a clinical-stage company whose future hinges on a single experimental therapy; the other is a commercial-stage business already scaling an approved product launch. This stock comparison is most relevant to traders and investors seeking to understand how risk profile, revenue generation, and market positioning diverge between an early-stage developer and a larger, revenue-producing biopharmaceutical firm. Both operate in the healthcare sector, yet their relative performance, sentiment, and catalysts differ sharply in the current market environment.
ENGN Overview and Recent Performance
ENGN is enGene Therapeutics Inc., a clinical-stage genetic-medicines company based in Montreal. Its lead investigational product, detalimogene voraplasmid, is being developed for non-muscle invasive bladder cancer (NMIBC), a form of cancer confined to the bladder lining. The therapy has received Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations from the U.S. Food and Drug Administration, and it is advancing through the Phase 2 LEGEND study.
In recent weeks, the stock has traded near the lower end of its 52-week range, reflecting a meaningful drawdown from earlier highs and a market capitalization of roughly $100 million to $120 million. As a pre-revenue company, ENGN remains highly sensitive to clinical data readouts and financing decisions. Recent restructuring measures, including workforce reductions and executive transitions, have added to investor caution, even as the company has reported favorable complete-response data from its lead program and continues to prepare for a potential Biologics License Application (BLA) submission.
INSM Overview and Recent Performance
INSM is Insmed Incorporated, a global biopharmaceutical company focused on serious respiratory diseases. Its commercial portfolio includes BRINSUPRI (brensocatib), the first approved therapy for non-cystic fibrosis bronchiectasis (NCFB), and ARIKAYCE (amikacin liposome inhalation suspension) for a type of nontuberculous mycobacterial (NTM) lung disease. The company is also advancing treprostinil palmitil inhalation powder (TPIP) across multiple Phase 3 studies for pulmonary arterial hypertension and related conditions.
Recent market activity has been shaped by a strong quarterly report in which total revenue grew substantially year over year, driven by accelerating BRINSUPRI sales. Management raised full-year revenue guidance, and the company launched BRINSUPRI in Japan, its first major ex-U.S. market. Despite this commercial momentum, the shares have declined notably from their 52-week high over the trailing year and remain negative year to date, as investors weigh ongoing net losses, cash burn, and a valuation still priced for future pipeline success.
Trending AI Robots
For traders who prefer a data-driven, systematic approach, Tickeron's Trending AI Robots page offers a curated view of automated strategies currently suited to prevailing market conditions. Tickeron hosts hundreds of AI trading bots that trade thousands of different tickers, but only a select group earns placement in this section. Each bot operates with its own trading style, strategy, timeframe, performance history, and set of tickers, ranging from short-term momentum models to longer-horizon trend-following systems. The featured robots are chosen based on their recent statistical performance and alignment with the current market regime, helping investors screen for strategies that match their own risk tolerance. Explore the Trending AI Robots page to review the latest candidates and their track records.
Head-to-Head Comparison
The central contrast between these two names is stage of development. INSM generates material product revenue and is scaling a commercial franchise, giving it greater financial visibility, while ENGN is entirely dependent on clinical outcomes and future regulatory milestones. In terms of market capitalization, INSM is orders of magnitude larger, which typically implies lower percentage volatility than a micro-cap like ENGN.
Growth drivers also differ. INSM's near-term catalyst is execution on the BRINSUPRI launch and pipeline data for TPIP, whereas ENGN's catalyst set revolves around Phase 2 data maturation and a potential BLA filing. Risk factors are elevated on both sides: ENGN faces binary clinical and financing risk, while INSM faces execution, cash-burn, and valuation risk. Sentiment, as measured by analyst ratings, currently leans strongly toward INSM.
Tickeron AI Verdict
Weighing trend consistency, stability, commercial traction, and relative positioning, Tickeron's AI would most likely favor INSM over ENGN in the current environment. INSM offers a more established, revenue-generating business with multiple catalysts and a stronger analyst consensus, whereas ENGN remains a higher-risk, pre-revenue development story subject to greater drawdown and uncertainty. This conclusion is probabilistic rather than definitive, reflecting observable factors such as business maturity, recent financial performance, and market sentiment rather than a guarantee of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENGN is a Buy and INSM is a Buy.
ENGN in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 02, 2026
ENGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 21 of 23 cases where ENGN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ENGN's RSI Indicator exited the oversold zone, 18 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ENGN as a result. In 48 of 54 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for ENGN just turned positive on November 04, 2026. Looking at past instances where ENGN's MACD turned positive, the stock continued to rise in 21 of 27 cases over the following month. The odds of a continued upward trend are 78%.
Following a +5.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENGN advanced for three days, in 129 of 152 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
ENGN moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ENGN crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for ENGN entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.509) is normal, around the industry mean (3.498). P/E Ratio (-0.845) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. ENGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
INSM's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for INSM turned positive on October 27, 2026. Looking at past instances where INSM's MACD turned positive, the stock continued to rise in 42 of 52 cases over the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on INSM as a result. In 66 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
INSM moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where INSM advanced for three days, in 201 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
INSM broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for INSM entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. INSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.982) is normal, around the industry mean (3.498). P/E Ratio (-27.768) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (23.148) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
INSM | ||
|---|---|---|
OUTLOOK RATING 1..100 | 35 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 54 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 57 | |
P/E GROWTH RATING 1..100 | 54 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ENGN | INSM | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 78% | 2 days ago 72% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 78% |
| Momentum ODDS (%) | 2 days ago 89% | 2 days ago 69% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 81% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 71% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 75% |
| Advances ODDS (%) | 3 days ago 85% | 2 days ago 69% |
| Declines ODDS (%) | 20 days ago 82% | 9 days ago 76% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 77% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ENGN’s FA Score shows that 0 FA rating(s) are green while INSM’s FA Score has 0 green FA rating(s).
- ENGN’s FA Score: 0 green, 5 red.
- INSM’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ENGN’s TA Score shows that 5 TA indicator(s) are bullish while INSM’s TA Score has 4 bullish TA indicator(s).
- ENGN’s TA Score: 5 bullish, 5 bearish.
- INSM’s TA Score: 4 bullish, 5 bearish.
Price Growth
ENGN (@Biotechnology) experienced а +3.09% price change this week, while INSM (@Biotechnology) price change was +14.41% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ENGN is expected to report earnings on Dec 28, 2026.
INSM is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ENGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ENGN has been closely correlated with TRDA. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if ENGN jumps, then TRDA could also see price increases.
| Ticker / NAME | Correlation To ENGN | 1D Price Change % | ||
|---|---|---|---|---|
| ENGN | 100% | -5.65% | ||
| TRDA - ENGN | 75% Closely correlated | +11.94% | ||
| COGT - ENGN | 48% Loosely correlated | -5.66% | ||
| PHAR - ENGN | 43% Loosely correlated | +0.46% | ||
| INSM - ENGN | 42% Loosely correlated | +2.92% | ||
| ASBP - ENGN | 36% Loosely correlated | +0.06% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| XLCI | 22.69 | 0.09 | +0.38% |
| State Street Communication Services Select Sector SPDR Premium Income ETF (XLCI) | |||
| OPER | 100.17 | 0.01 | +0.01% |
| ClearShares Ultra-Short Maturity ETF (OPER) | |||
| NVBT | 40.07 | -0.10 | -0.25% |
| AllianzIM U.S. Equity Buffer10 Nov ETF (NVBT) | |||
| AVIG | 39.96 | -0.28 | -0.70% |
| Avantis Core Fixed Income ETF (AVIG) | |||
| ICOP | 47.94 | -1.52 | -3.07% |
| iShares Copper and Metals Mining ETF (ICOP) | |||